阿托伐他汀对急性心肌梗死择期冠状动脉介入治疗患者造影剂肾病的防治作用

167例急性心肌梗死患者行冠状动脉介入治疗术前随机分为试验组(84例,阿托伐他汀80mg/d)和对照组(83例,阿托伐他汀20mg/d).给药7 d后行冠状动脉介入术.与术前24 h比较,术后两组患者血清高敏C反应蛋白(ha-CRP)和血清肌酐均升高,肾小球滤过率降低(均P<0.05);与对照组比较,试验组术前24 h、术后血清hs-CRP和血肌酐较低,肾小球滤过率较高(均P<0.05);试验组造影剂肾病发生率为7%(6/84),低于对照组18%(15/83)(P<0.05).提示急性心肌梗死择期冠状动脉介入治疗患者术前口服大剂量阿托伐他汀可能通过抑制炎症发挥预防造影剂肾病作用.

Prevention of contrast-induced nephropathy with atorvastatin in patients with acute myocardial infarction undergoing elective percutaneous coronary intervention

The study intended to evaluate the effect of high-dese atorvastafin on serum high sensitive C-reactive protein (hs-CRP) and renal function in patients with acute myocardial infarction undergoing elective pereutancous coronary intervention ( PCI ). One hundred and sixty seven patients were randomly divided into two groups: in test group (n =84) patients received oral atorvastatin 80 mg/d and in control group (n = 83) patients received atorvastatin 20 mg/d, the medication in both groups was lasted for 7 days before PCL Compared to levels at 24 h before PCI, serum hs-CRP and creatinine levels at 48 h after PCI were increased in both groups ( both P < 0. 05), and glomerular filtration rate was decreased ( P < 0. 05 ). Compared to control group, serum hs-CRP and creatinine levels 24 h before PCI and 48 h after PCI in test group were significantly lower, and glomerular filtration rate was significantly higher (P <0. 05, respectively). The incidence of contrast-induced nephropathy was lower in test group than that in control group[7% (6/84) vs.18% (15/83), P <0.05]. The results indicate that high-dose atorvastatin might be effective in protecting patients with acute myocardial infarction undergoing elective PCI from contrast-induced nephropathy via inflammatory response inhibition.